Name

Genetic Immunity

Legal name

GI.HU Ltd.

Website

https://www.geneticimmunity.hu

Company type

Private

Operating status

Operating

Ownership category

akta.pro rank

Product category

Therapeutic Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

Keywords

• DNA therapeutic vaccines
• HIV immunotherapy
• Transdermal vaccine delivery
• Plasmid DNA platform
• Biopharmaceutical research

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. DermaVir Therapeutic Vaccine: Pre-revenue clinical-stage biotech company. DermaVir is in clinical development for HIV/AIDS treatment. Future revenue will come from pharmaceutical product sales following regulatory approval. The company plans to release clinical batches in the European Union following GMP guidelines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Genetic Immunity develops DNA-based therapeutic vaccines administered transdermally to treat HIV and other viral infections and cancers. Its lead product candidate DermaVir® is a plasmid DNA-based vaccine formulated with proprietary PEIm polymer to create synthetic pathogen-like particles that boost natural immune responses to kill HIV-infected cells. The DermaPrep® skin-patch system delivers the vaccine to Langerhans cells without needles, and the platform is adaptable to other diseases by swapping the pDNA construct.

Product overview

Genetic Immunity offers a unified therapeutic vaccine platform centered on its lead product candidate DermaVir®, a DNA-based therapeutic vaccine for HIV/AIDS treatment. The platform is supported by DermaPrep®, a transdermal administration system using a skin patch for vaccine delivery. The technology uses disease-specific plasmid DNA constructs (active pharmaceutical ingredients) formulated with a novel synthetic polymer (PEIm) to create pathogen-like particles that target Langerhans cells in the skin, enabling transdermal immunization. The platform is designed to treat viral infections and certain types of cancer by evoking antigen-specific cytotoxic T-cell responses.

Differentiator

Problem solved

Functional benefit

Products and services

• DermaVir® A lead clinical-stage DNA-based therapeutic vaccine designed to boost natural immune responses to kill HIV-infected cells in patients with compromised immunity. It directs the immune system to actively fight HIV through antigen-specific cytotoxic T-cell responses and has shown statistically significant reduction of HIV-RNA versus placebo in completed clinical studies.
• DermaPrep®

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Universities and Research InstitutescoreStrategic or Co-development PartnerMultidisciplinary research team collaborates with several universities and research institutes across the world on therapeutic vaccine development. The company has developed its organization and quality control system in cooperation with important universities.
• Contracted Manufacturing PartnerscoreStrategic or Co-development PartnerCompany cooperates with contracted manufacturing partners for therapeutic vaccine production. Quality control systems are aligned with GMP (Good Manufacturing Practice) guidelines for Investigational Medicinal Products for human use in the European Union.

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• BioNTech: mRNA therapeutics and vaccines leader with infectious disease and oncology pipeline. Comparable as a nucleic-acid platform peer whose technology could be redirected into HIV therapeutic vaccines.
• Gilead Sciences: Global HIV market leader with Biktarvy and other ART franchises, plus cure research. Comparable as the dominant commercial incumbent whose ART franchise defines the standard of care Genetic Immunity's therapeutic vaccine would complement.
• ViiV Healthcare: HIV-focused specialty company majority-owned by GSK (with Pfizer and Shionogi). Comparable as a large, HIV-specialized incumbent pursuing long-acting ART and cure-adjacent modalities that compete for the same patient population.
• Moderna: mRNA platform leader developing vaccines and therapeutics across infectious disease and oncology, with HIV vaccine candidates (e.g., mRNA-1644). Comparable as a nucleic-acid vaccine platform peer expanding into HIV.
• Johnson & Johnson: Diversified pharma with HIV vaccine and cure research programs (e.g., mosaic vaccine and bnAb collaborations) via Janssen. Comparable as a large incumbent exploring HIV cure immunologic approaches alongside ART.

Direct peers

• Inovio Pharmaceuticals: DNA-based vaccine and immunotherapy developer with HIV vaccine candidates (e.g., PENNVAX®) using plasmid DNA delivered via electroporation. Most directly comparable as a peer DNA-vaccine platform targeting infectious diseases including HIV.
• Immune Response BioPharma: Clinical-stage biotech developing immune-based therapies, including HIV vaccine candidates (e.g., NeuroVax and Remune). Comparable as a peer in HIV-directed immunotherapeutic vaccines.
• Excision BioTherapeutics: Clinical-stage gene-editing company developing EBT-101, a CRISPR-based in vivo therapy for functional cure of HIV. Comparable as a small, HIV cure-focused biotech pursuing a single-dose functional cure.
• Vir Biotechnology: Clinical-stage immunology company with an HIV cure program (e.g., VIR-1111 and broadly neutralizing antibody collaborations). Comparable as a peer using immunologic mechanisms to address the HIV reservoir.
• American Gene Technologies: Clinical-stage gene and cell therapy company developing AGT103-T, an autologous lentiviral therapy intended to functionally cure HIV. Comparable as a small, HIV cure-focused biotech pursuing immune-mediated eradication of infected cells.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genetic Immunity